June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey May 14, 2021 GBS Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights April 15, 2021 GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update December 28, 2020 GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering December 23, 2020 UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering December 22, 2020 GBS Inc. Announces Pricing of Initial Public Offering May 29, 2020 The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test May 6, 2020 FDA Engagement Commences for Saliva Glucose Biosensor in the US
June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
April 15, 2021 GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
May 29, 2020 The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test
